Bioasis Technologies Inc. has recently announced partnerships for its xB3 pharmaceutical platform with Janssen Biotech and Nueramedy, along with the acquisition of Cresence AS' Epidermal Growth...
The blood-brain barrier is a major hurdle in treating a whole range of diseases affecting the CNS. While it serves a vital role in protecting against...
Estimated as a $3 billion opportunity for Bioasis Technologies, the company's xB3 platform is set to revolutionize the treatment of neurological disease. The technology helps deliver...
Bioasis Technologies’ new xB3 platform overcomes a major hurdle in the fight against neurological disease: the blood-brain barrier (BBB). Potentially worth billions of dollars in licensing...